Lantheus (NASDAQ:LNTH) Issues Quarterly Earnings Results

Key Points

• Lantheus beat Q1 expectations, reporting adjusted EPS of $1.46 versus the $1.25 consensus and revenue of $377.3 million versus $354.5 million expected. Revenue was up 1.2% year over year, and the company’s net margin and return on equity remained strong.
• The company raised FY2026 guidance to $5.00–$5.25 in adjusted EPS and reaffirmed revenue guidance of $1.40–$1.45 billion. Management also highlighted strong cash flow generation in the quarter, with operating cash flow of $125.1 million and free cash flow of $121.9 million.
• Pipeline and product updates were a major focus, including FDA approval of PYLARIFY TruVu and continued momentum for NeuraCeq. Lantheus also said PNT2003 received tentative FDA approval, while MK-6240 has a PDUFA date set for August 13, 2026.

Lantheus (NASDAQ:LNTH - Get Free Report) issued its quarterly earnings data on Thursday. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.25 by $0.21, FiscalAI reports. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million during the quarter, compared to analysts' expectations of $354.48 million. During the same period in the previous year, the company earned $1.53 earnings per share. Lantheus's revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus updated its FY 2026 guidance to 5.000-5.250 EPS.

Here are the key takeaways from Lantheus' conference call:

• FDA approved PYLARIFY TruVu (Mar 6); the new formulation enables larger batch sizes at high‑energy cyclotrons and will be transitioned site‑by‑site beginning in Q4 2026, with meaningful revenue expected in 2027 once HCPCS/TPT coding, payer readiness, and PMF approvals are in place.
• Q1 financials showed resilience — revenue of $377.3M (+1.2% YoY; +8.6% ex‑SPECT), strong operating cash flow ($125.1M) and free cash flow ($121.9M), PYLARIFY U.S. volume +5.8% YoY, and management reiterated 2026 guidance of $1.40–$1.45B revenue and $5.00–$5.25 adjusted EPS.
• NeuraCeq momentum — Q1 revenue $35.4M (14.3% q/q vs Q4 2025), positioning as the fastest‑growing beta‑amyloid agent with a growing PMF footprint (22 sites) to expand supply and deepen penetration amid DMT adoption and earlier diagnostic guidelines.
• PNT2003 received FDA tentative approval for GEP‑NETs (LUTATHERA equivalent), but final commercialization depends on the Hatch‑Waxman stay, related legal proceedings, and manufacturing/commercial readiness, and it is not materially included in 2026 guidance.
• Late‑stage pipeline catalysts — MK‑6240 (tau PET) has a PDUFA date of Aug 13, 2026 and is widely used in Alzheimer’s DMT trials; the company is prioritizing radiodiagnostics and selectively allocating capital while evaluating options for radiotherapeutic assets.

Lantheus Stock Performance

NASDAQ:LNTH traded up $2.06 during trading hours on Friday, hitting $93.06. 1,540,225 shares of the company traded hands, compared to its average volume of 804,357. The stock has a market capitalization of $6.06 billion, a price-to-earnings ratio of 22.42 and a beta of -0.08. Lantheus has a twelve month low of $47.25 and a twelve month high of $94.86. The firm has a 50-day moving average of $79.69 and a 200 day moving average of $68.87. The company has a current ratio of 2.83, a quick ratio of 2.51 and a debt-to-equity ratio of 0.47.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LNTH. The Goldman Sachs Group restated a "neutral" rating and issued a $94.00 price objective on shares of Lantheus in a research note on Thursday. Jefferies Financial Group restated a "buy" rating and issued a $110.00 price objective on shares of Lantheus in a research note on Tuesday, March 17th. B. Riley Financial restated a "buy" rating on shares of Lantheus in a research note on Friday, May 1st. William Blair restated an "outperform" rating on shares of Lantheus in a research note on Tuesday, March 17th. Finally, Mizuho boosted their price objective on shares of Lantheus from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Friday. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $97.29.

Hedge Funds Weigh In On Lantheus

Large investors have recently bought and sold shares of the stock. UMB Bank n.a. raised its stake in Lantheus by 104.1% during the 4th quarter. UMB Bank n.a. now owns 955 shares of the medical equipment provider's stock valued at $64,000 after purchasing an additional 487 shares during the last quarter. Inceptionr LLC acquired a new position in Lantheus during the 4th quarter valued at $209,000. Advisory Services Network LLC acquired a new position in Lantheus during the 3rd quarter valued at $120,000. New Vernon Capital Holdings II LLC acquired a new position in Lantheus during the 3rd quarter valued at $147,000. Finally, iSAM Funds UK Ltd acquired a new position in Lantheus during the 3rd quarter valued at $224,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Lantheus reported first-quarter EPS of $1.46, beating estimates of $1.25, on revenue of $377.3 million, also above expectations. The beat suggests solid underlying demand and execution. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company issued FY2026 EPS guidance of $5.00 to $5.25, slightly above the consensus estimate, reinforcing expectations for continued profitability. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Citizens JMP raised its price target to $115 from $85 and reiterated a Market Outperform rating, implying meaningful upside from current levels. Tickerreport.com
• Positive Sentiment: Mizuho also lifted its price target to $100 from $95 and kept an Outperform rating, adding to the bullish post-earnings analyst momentum. Benzinga
• Neutral Sentiment: Several follow-up stories highlighted valuation and the earnings call transcript, but these were mainly commentary on the already-reported results rather than new catalysts. Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.